Overview

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The primary aim is to determine the rate of major bleeding and blood clots when using enoxaparin as a bridge to oral blood thinning medication in patients who have undergone mechanical valve replacement.
Phase:
Phase 4
Details
Lead Sponsor:
The Cleveland Clinic
Treatments:
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight